期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

大剂量阿托伐他汀联合水化对老年急诊PCI术后造影剂肾病保护作用的研究 被引量：2

下载PDF
导出
摘要 目的:探讨阿托伐他汀联合水化对老年人群急诊冠状动脉介入术(PCI)后造影剂肾病的保护作用。方法:92例患者随机分为大剂量强化治疗组、常规剂量组、空白对照组,3组患者在水化治疗的基础上,大剂量强化治疗组及常规剂量治疗组入院后分别给予阿托伐他汀口服80mg、20mg,急诊PCI术后3d内分别给予阿托伐他汀钙片40mg/d、20mg/d口服;空白对照组:在术前未给予他汀类药物。分别测定并比较3组患者术后24,72h的血肌酐(Scr)、尿素氮(BUN)、内生肌酐清除率(Ccr)以及造影剂肾病的发生率。结果:术后24h与术前相比:对照组、常规剂量组BUN、Scr和Ccr均显著升高(P<0.05),大剂量强化治疗组BUN、Ccr升高不显著(P>0.05),仅Scr有轻度升高(P<0.05),且Scr比其余两组低,差异有统计学意义(P<0.05)。术后72h各组BUN、Scr和Ccr均恢复至术前水平(P>0.05)。结论:大剂量阿托伐他汀联合水化对老年急诊PCI术后造影剂肾病具有一定的保护作用。
作者 何贵新 谭炜
机构地区 广西中医药大学第一附属医院心血管内科
出处 《广西医科大学学报》 CAS 2012年第4期583-585,共3页 Journal of Guangxi Medical University
关键词 阿托伐他汀 急性心肌梗死 造影剂肾病 保护作用
分类号 R541.4 [医药卫生—心血管疾病]
  • 相关文献

参考文献13

  • 1姜文兵,傅国胜.造影剂肾病预防的研究进展[J].临床荟萃,2006,21(12):897-900. 被引量：23
  • 2Asif A,Preston RA,Roth D, Radiocontrast-induced Ne-phropathy[J]. Am J Ther,2003,10 :137-147.
  • 3Moscucci M,Kline-Rogers E, Shsre D,et al. Simple bedside additive tool for prediction of in-hospital mortality after percutaneous coronary interventions [ J ]. Circulation,2001,104(3) :263-268.
  • 4Lecian D,Demova H, Lodererova A, et al. Renal effects of HMG~CoA reductase inhibition in a rat model of chronic inhibition of nitric oxide synthesis [J]. Kidney Blood Press Res,2006,29(3) : 135-143.
  • 5Patti G, Nusca A,Chello M, et al. Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention[J]. Am J Cardiol,2008,101(2) :279-285.
  • 6Ma YC,Zuo L,Chen JH,et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kid-hey disease [ J]. J Am Soc Nephrol. 2006,17(10):2 937-2 944.
  • 7Rihal CS,Textor SC,Grill DE,et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention [J]. Circulation, 2002, 105(19):2 259-2 264.
  • 8Asif A,Epstein M. Prevention of radioncontrast-induced nephrops-thy[J]. Am J Kidney Dis,2004,44(1) : 12.
  • 9Attallah N,Yassine L,Musial J,et al. The potential role of statins in contrast nephropathy [J ]. Clin Nephml, 2004,62⑷:273-278.
  • 10Ozhan H, Erden I,Ordu S, et al. Efficacy of short-term high-dose atorvastatin for prevention of contrast-in-duced nephropathy in patients undergoing coronary an-giography[J]. Angiology,2010 ,61(7) :711-714,.

二级参考文献26

  • 1Zager RA,Johnson AC,Hanson SY.Radiographic contrast media-induced tubular injury:evaluation of oxidant stress and plasma membrane integrity[J].Kidney Int,2003,64(1):128-139.
  • 2Alonso A,Lau J,Jaber BL,et al.Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease:a meta-analysis of randomizes,controlled trials[J].Am J Kidney Dis,2004,43(1):1-9.
  • 3Isenbarger DW,Kent SM,O'Malley PG.Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy[J].Am J Cardiol,2003;92(12):1454-1458.
  • 4Birck R,Krzossok S,Markowetz F,et al.Acetylchsteine for prevention of contrast nephropathy:meta analysis[J].Lancet,2003,362(9384):598-603.
  • 5Briguori C,Colombo A,Violante A,et al.Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity[J].Eur Heart J,2004,25(3):206-211.
  • 6Goldenberg I,Shechter M,Matetzky S,et al.Oral acetylcysteine as an adjunt to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography.A randomized controlled trial and review of the current literature[J].Eur Heart J,2004,25(3):212-218.
  • 7Esnault VL.Radiocontrast media-induced nephrotoxicity in patients with renal failure:rationale for a new double-blind,prospective,randomized trial testing calcium channel antagonists[J].Nephrol Dial Transplant,2002,17(8):1362-1364.
  • 8Oldroyd SD,Morcos SK.Endothelin:what does the radiologist need to know?[J].Br J Radiol,2000,73(876):1246-1251.
  • 9Wang A,Holcslow T,Bashore TM,et al.Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism[J].Kidney Int,2000,57(4):1675-1680.
  • 10Kini AS,Mitre CA,Kamran M,et al.Changing trends in incidence and percutaneous coronary intervention with use of fenoldopam[J],2002,89(8):999-1002.

共引文献22

同被引文献13

  • 1Kini AS,Sarkar K,Rafael OC,et al. Serum creatinine ratio :a novel predictor of mortality after percutaneous coronaryintervention in patients with normal and abnormal renalfunction[ J]. Catheter Cardiovasc Interv,2009,74( 1) :49.
  • 2Satler LF. A plan to reduce contrast induced nephropathy[J]. Catheter Cardiovasc Interv,2013 ,82(6) ;898.
  • 3Mehran R, Aymong ED, Nikolsky E, et al. A simple riskscore for prediction of contrast-induced nephropathy afterpercutaneous coronary intervention : development and ini-tial validation[ J]. J Am Coll Cardiol,2004 ,44(7) : 1393.
  • 4Fishbane S. N - acetylcysteine in the prevention of contrast-in-duced nephropathy [ J ]. Clin J Am Soc Nephrol, 2008,3(1):281.
  • 5Gu GQ,Lu R,Cui W,et al. Low-dose furosemide adminis-tered with adequate hydration reduces contrast-induced ne-phropathy in patients undergoing coronary angiography [ J ].Cardiology,2013,125(2) :69.
  • 6Seifirad S,Masoudkabir F. Apelin could reduce risk of con-trast-induced nephropathy in patients with congestive heartfailure[ J]. Med Hypotheses ,2013 ,81 (5 ) :898.
  • 7Efstratiadis S,Michaels AD. Acute hemodynamic effects ofintravenous nesiritide on left ventricular diastolic functionin heart failure patients[ J]. J Card Fail ,2009 ,15(8) :673.
  • 8Elkayam U , Akhter MW, Liu M , et al. Assessment of renalhemodynamic effects of nesiritide in patients with heartfailure using intravascular doppler and quantitative angiog-raphy [ J ].JACC Cardiovasc Imaging,2008 ,1(6) :765.
  • 9张晶,傅向华,樊欣娜,贾新未,谷新顺,李世强,姜云发,范卫泽,苏建玲.急性前壁心肌梗死伴心力衰竭患者急诊经皮冠状动脉介入治疗围手术期应用重组人B型钠尿肽的心肾保护效应[J].中国危重病急救医学,2010,22(11):669-673. 被引量：25
  • 10佟丽,王彩虹,杨立宏.造影剂肾病的研究现状[J].医学综述,2012,18(12):1870-1872. 被引量：6

引证文献2

二级引证文献7

广西医科大学学报
2012年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部